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Received February 19, 2010; accepted November 2, 2010AbstractBackground: T1-weighted (T1W) hyperintense nodules against a background of cirrhosis are diagnostically challenging in daily practice. All
regenerative nodules, dysplastic nodules and hepatocellular carcinoma (HCC) might present hyperintense on T1W imaging (T1WI), so T1W
hyperintense nodules cannot be definitively characterized as dysplastic nodules or HCC before biopsy, resection or transplantation. The purpose
of our study was to evaluate Ferucarbotran-enhanced Magnetic Resonance Imaging (MRI) with accumulation-phase fat suppression T1-weighted
imaging (FS-T1WI) in comparison with gadolinium-enhanced MRI for characterization of hyperintense nodules on unenhanced T1WI within
cirrhotic liver.
Methods: Two separate groups of patients with histologically-proven T1W hyperintense nodule on MRI were retrospectively identified. The
Ferucarbotran group consisted of 17 T1W hyperintense nodules in 12 patients. The gadolinium group consisted of 22 T1W hyperintense nodules
in 21 patients. All of the patients had liver cirrhosis. Finally, 11 HCC nodules, and six benign nodules were included in the Ferucarbotran group;
15 HCC nodules and seven benign nodules were included in the gadolinium group.
Results: With the conventional criteria, in the gadolinium-enhanced group, the sensitivity, specificity, and accuracy were 53%, 100%, and 73%,
respectively. Using the conventional criteria in the Ferucarbotran group, the sensitivity, specificity, and accuracy were 73%, 100%, 82%,
respectively. Using the conventional criteria plus hyperintense on the accumulation-phase FS-T1WI in the Ferucarbotran group for character-
ization of the T1W hyperintense nodules, the sensitivity, specificity, and accuracy were 100%, 83%, 94%, respectively. The sensitivity of
Ferucarbotran-enhanced MR with accumulation-phase FS-T1WI was better than that of gadolinium-enhanced MRI ( p¼ 0.01).
Conclusion: Ferucarbotran-enhanced MRI with accumulation-phase FS-T1WI is superior to gadolinium-enhanced MRI in characterization of
T1W hyperintense nodules within cirrhotic liver. T1W hyperintense nodule within cirrhotic liver depicting hyperintense on Ferucarbotran-
enhanced accumulation-phase FS-T1WI should be investigated aggressively.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Cirrhosis is a diffuse liver disease that is characterized by
fibrosis and nodular regeneration. Hepatocellular carcinoma* Corresponding author. Dr. Ran Chou Chen, Department of Radiology,
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doi:10.1016/j.jcma.2011.01.013(HCC) develops by means of a multi-step dedifferentiation
process that progresses from regenerative nodule to dysplastic
nodule and then to HCC.1 Hepatic resection or transplantation
is the most effective treatment for HCC if the diagnosis is
made at an early stage.2 Accurate preoperative imaging for the
detection of HCC or dysplastic nodule is therefore crucial.
T1-weighted (T1W) hyperintense nodules on unenhanced
T1W imaging (T1WI) against a background of cirrhosis arehinese Medical Association. All rights reserved.
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nodules, dysplastic nodules, and HCC might present hyper-
intense on unenhanced T1WI, so T1W hyperintense nodules
cannot be definitively characterized as dysplastic nodules or
HCC before biopsy, resection or transplantation.3e5
Positive arterial enhancement during dynamic Magnetic
Resonance Imaging (MRI) is a well-known criterion in diag-
nosis of HCC.6,7 Gadolinium-enhanced multiphase dynamic
imaging has generally been used for the vascular assessment
of focal lesions in cirrhotic liver.6e8 However, determination
of contrast enhancement is not always easy to accomplish for
T1W hyperintense lesions in arterial phase during dynamic
imaging.9
Superparamagnetic iron oxide (SPIO) is a liver-specific
particulate MRI contrast agent that is primarily taken up by
the Kupffer cells of the liver. SPIO-enhanced MRI reflects
Kupffer-cell numbers in HCCs and is useful for estimation of
histological grading in HCCs.10 The uptake clustered particles
can produce the susceptibility effect and cause loss of signal
intensity on both postcontrast T2W and T1W images.11 We
hypothesized that Ferucarbotran-enhanced MRI might be
superior to gadolinium-enhanced MRI in characterization of
T1W hyperintense nodules within cirrhotic liver. To our
knowledge, this had not been investigated previously. The
purpose of our study was to evaluate the Ferucarbotran-
enhanced MRI with accumulation-phase fat suppression
T1WI in comparison with gadolinium-enhanced MRI for
characterization of hyperintense nodules on unenhanced
T1WI within cirrhotic liver.
2. Methods2.1. Patient populationApproval for retrospective study was obtained from our
institutional review board. Two separate groups of patients
with focal hepatic lesions who had received liver biopsy or
surgery from January 2004 to December 2006 were retro-
spectively identified from medical records. One patient
group had undergone Ferucarbotran-enhanced MRI, and the
other group underwent gadolinium-enhanced MRI. An
attending radiologist with more than 10 years’ experience in
hepatic MRI retrieved the images and conducted a prelimi-
nary review on the picture archiving and communication
system (PACS) monitor for the initial selection of patients
and lesions among the patients. The criteria for entry into
the analysis were as follows: (1) The nodule which under-
went histological examination should present hyperintense
on T1W opposed-phase imaging; (2) The time interval
between initial MR study and histological examination
should be less than one month; and (3) The diagnosis of
HCCs should be based on histological examination. For
nodules with benign histological result, follow-up imaging
study should be performed for at least one year. When the
benign nodule was stable in size for at least one year, it
was confirmed as a benign lesion. When the benign nodule
was enlarged or depicted arterial enhancement during thefollow-up period, it was considered as a benign nodule with
malignant potential.2.2. Ferucarbotran patient groupThe Ferucarbotran patient population consisted of 17 T1W
hyperintense nodules (mean size, 2.0 1.1 cm) in 12 patients
(10 men and 2 women) who ranged in age from 28 to 83 years
(mean age: 56 years). The other nodules of the 12 patients
without histological examination were ignored. All patients
had liver cirrhosis and chronic hepatitis (hepatitis B, eight
patients; hepatitis C, two patients; hepatitis B and C, two
patients). Seven patients had a solitary lesion, five patients had
two lesions. Two nodules in two patients underwent surgical
resection. Fifteen nodules in 10 patients received needle
biopsy. One benign nodule (1.3 cm in size) was enlarged and
depicted arterial enhancement during dynamic study on the
follow-up Computed tomography (CT) and MRI. The other
five histologically benign nodules showed no obvious changes
on the follow-up MRI studies (mean period, 20 months).
Finally, 11 HCC nodules, five benign nodules, and one benign
nodule with malignant potential were diagnosed.2.3. Gadolinium patient groupThe gadolinium patient population consisted of 22 T1W
hyperintense nodules (mean size, 2.1 0.7 cm) in 21 patients
(13 men and 8 women) who ranged in age from 30 to 78 years
(mean age: 62 years). The other nodules of the 21 patients
without histological examination were ignored. Eighteen
patients had liver cirrhosis and chronic hepatitis (hepatitis B, 9
patients; hepatitis C, 5 patients; hepatitis B and C, 4 patients),
and 3 patients had alcoholic cirrhosis. Twenty patients had
a solitary lesion, and one patient had two lesions. Two nodules
in two patients underwent surgical resection. Twenty nodules
in 19 patients received needle biopsy. The seven benign
nodules showed no obvious changes on the follow-up MRI
studies (mean period, 17 months). Finally, 15 HCC nodules
and 7 benign nodules were diagnosed.2.4. MRIAll MRI (for both Ferucarbotran and gadolinium study
groups) was performed with a 1.5-T MR system (Philips
Gyroscan ACS-NT, Best, The Netherlands), equipped with
a body phased-array coil. Unenhanced MRI was performed
with T2W turbo spin-echo (TSE) axial imaging (T2WI,
TR/TE: 2500/90 ms; turbo spin-echo factor, 23; slice thickness
8 mm, gap 0.8 mm) without and with fat suppression (FS)
under respiratory trigger, T2*-echo planar imaging (EPI)
(TR/TE 500/13.8 ms; angle, 35) obtained during one-breath
hold, T1-weighted dual echo imaging (TR/TE: 210/2.3 ms and
4.6 ms; slice thickness 8 mm, gap 0.8 mm) during one or two
breath-holdings according to the liver size of the patients.
Automatic shimming was applied for fat saturation imaging to
maximize magnetic field homogeneity. Flow compensation
was also used.
64 C.-T. Chou et al. / Journal of the Chinese Medical Association 74 (2011) 62e682.5. Ferucarbotran-enhanced MRIFerucarbotran (Resovist, Schering, Germany), consisting of
SPIO microparticles coated with carboxydextran, was pre-
loaded at volume of 1.4 mL (>50 kg body weight) into
a connecting intravenous tube and manually injected rapidly
through a filter with a 5-mm pore size. Dynamic T1W fast field
echo (FFE) imaging (175e210/1.3e2.1; flip angle, 80) was
carried out before, 18e20 seconds and 50e55 seconds after
the contrast agent injection. An equilibrium-phase T1W with
FS imaging (FS-T1WI, TR/TE 241e344/2.7 ms, flip angle,
70; slice thickness 8 mm, gap 0.8 mm) with breath-holding
was performed 180 seconds after the contrast agent injection.
Approximately 10 minutes after intravenous injection of the
SPIO agent, the postcontrast accumulation-phase images,
including T2W axial imaging without and with FS, T2*-EPI,
were performed using the same parameters as the precontrast
sequences. Finally, FS-T1WI was performed after completion
of the postcontrast T2WI.2.6. Gadolinium-enhanced MRIGadopentetate dimeglumine (Magnevist; Schering, Berlin,
Germany) at 0.1 mmol Gd/kg body weight was manually
injected rapidly. Dynamic T1W FFE imaging (175e210/
1.3e2.1; flip angle, 80) was carried out before, 18e20
seconds and 50e55 seconds after the contrast agent injection.
An equilibrium-phase FS-T1W (TR/TE 241e344/2.7 ms, flip
angle, 70; slice thickness 8 mm, gap 0.8 mm) was performed
with breath-holding 180 seconds after the contrast agent
injection.2.7. Data analysisImaging analysis was performed on a dual-screen diag-
nostic workstation (GE Healthcare, Milwaukee, WI, USA).
All images were reviewed retrospectively by two radiologists
who had more than 10 years of experience in liver MRI. They
did not know the final diagnosis.
Only histologically-proven nodules which presented
hyperintense on the opposed-phase T1W images of the initial
MR study according to the position of ultrasonography-
guiding biopsy were reviewed. Signal intensity on T2WI and
enhancement patterns of the corresponding lesions on
contrast-enhanced dynamic images were also recorded. The
presence of arterial enhancement of the lesion was detected by
automatic subtraction of multiphasic dynamic study using the
software of the MR machine. The follow-up MR images of the
patients with benign T1W hyperintense nodule were reviewed
by the two same radiologists to assess the serial changes based
on viewing of both MR images. When the interpretations of
the two radiologists differed, a third radiologist joined the
discussion until consensus was reached.
The reviewers used the following criteria for characteriza-
tion of the T1W hyperintense nodules. The conventional HCC
diagnostic criteria for gadolinium-enhanced MR images were
nodule presented hyperintense on the precontrast T2WI orpresence of early arterial enhancement during dynamic MRI.6
The conventional HCC diagnostic criteria for Ferucarbotran-
enhanced MR images were nodule presented hyperintense on
the precontrast or postcontrast T2WI/T2*EPI or presence of
early arterial enhancement during dynamic MRI.6,7,10 Besides
the conventional criteria, when a nodule showed hyperintense
on the Ferucarbotran-enhanced accumulation-phase FS-T1WI,
the nodule was also diagnosed as HCC.12,132.8. Statistical analysisAn independent t test was used to compare continuous
variable, such as the patient’s age and tumor size, between the
Ferucarbotran-enhanced and gadolinium-enhanced groups.
Categorical variables, such as patient gender, background liver
disease (hepatitis, Child-Pugh class) were carried out using the
chi-square test. Chi-square test was also used to compare the
diagnostic difference between Ferucarbotran-enhanced and
gadolinium-enhanced groups and to compare the difference
between histological results of T1W hyperintense nodules.
Wilcoxon signed ranks test was used to compare the diag-
nostic difference between conventional criteria and accumu-
lation-phase FS-T1WI within Ferucarbotran-enhanced group.
The results were considered significant at p< 0.05. Kappa
statistic was performed to evaluate the inter-observer differ-
ence. The result was expressed as k values and could be
classified according to a scale, (poor, <0; slight, 0.0e0.20;
fair, 0.21e0.40; moderate, 0.41e0.60; good, 0.61e0.80; and
excellent, 0.81e1.00).
3. Results
In characterization of the T1W hyperintense nodules, an
excellent agreement of inter-observer agreement between the
two reviewers was noted in the Ferucarbotran-enhanced group
(k¼ 0.86) and the gadolinium-enhanced group (k¼ 0.81).
Overall, a consensus reading was necessary for one (1/17)
lesion in the Ferucarbotran group, and this was necessary for
two (2/22) lesions in the gadolinium-enhanced group.
With regard to patient’s age ( p¼ 0.54), gender ( p¼ 0.2),
background liver disease ( p¼ 0.94), and tumor size
( p¼ 0.28), there were no statistically significant differences
between the Ferucarbotran-enhanced and gadolinium-
enhanced groups. The histological grading of the T1W
hyperintense nodules in both groups is shown in Table 1.
When only HCCs were considered, the percentage of well-
differentiated HCC (20/26) was significantly higher than that
of moderately-differentiated HCC (6/26) ( p< 0.001).
Seventy-three percent (8/11) in the Ferucarbotran-enhanced
group, and 80% (12/15) in the gadolinium-enhanced group
were well-differentiated HCCs.
The tumor numbers, sizes, signal intensities on precontrast
T2WI and enhancing patterns for both groups are shown in
Table 2 and Table 3. In the Ferucarbotran-enhanced group,
seven nodules showed hyperintense on precontrast T2WI, four
nodules showed arterial enhancement during dynamic study
(Fig. 1), and eight nodules showed hyperintense on the
Table 1
Histological results of T1-weighted hyperintense nodules in both ferucarbo-
tran-enhanced and gadolinium-enhanced groups
Lesion type Pathology Ferucarbotran group Gadolinium group Total
HCC wHCC 8 12 20
mHCC 3 3 6
Benign nodule DN or RN 6a 7 13
a One of the nodules was enlarged with arterial enhancement in follow-up
computed tomography and magnetic resonance.
DN¼ dysplastic nodule; HCC¼ hepatocellular carcinoma; mHCC¼
moderately-differentiated HCC; RN¼ regenerative nodule; wHCC¼well-
differentiated HCC.
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intense or isointense on T2WI and no arterial enhancement
during dynamic study (Fig. 2). With the conventional HCC
diagnostic criteria, 8 of 11 HCC nodules in the Ferucarbotran-
enhanced group were correctly diagnosed. All of the HCC
nodules and the benign nodule with malignant potential
showed hyperintense on the accumulation-phase FS-T1WI.
There were three additional HCC nodules detected by the
accumulation-phase FS-T1WI.
In the gadolinium-enhanced group, five nodules showed
hyperintense on T2WI and eight nodules showed arterial
enhancement during dynamic study. With the conventional
HCC diagnostic criteria, 8 of 15 HCC nodules in the gadoli-
nium-enhanced group were correctly diagnosed. The other
nodules showed hypointense or isointense on T2WI and no
arterial enhancement during dynamic study.
The results of conventional HCC diagnostic criteria for
characterization of the T1W hyperintense nodules in the
gadolinium/Ferucarbotran-enhanced groups and conventional
criteria plus additional accumulation-phase FS-T1WI in
the Ferucarbotran group are shown in Table 4. Using the
conventional criteria in the gadolinium-enhanced group, the
sensitivity, specificity, and accuracy were 53%, 100%, and
73%, respectively. Using the conventional criteria in the
Ferucarbotran group, the sensitivity, specificity, and accuracy
were 73%, 100%, and 82%, respectively. Using the
conventional criteria plus accumulation-phase FS-T1WI for
characterization of the T1W hyperintense nodules, the
sensitivity, specificity and accuracy were 100%, 83%, and
94%, respectively. The sensitivity of Ferucarbotran-enhanced
MR with accumulation-phase FS-T1WI was significantly
higher than that of gadolinium-enhanced ( p¼ 0.01) andTable 2
Number, size, and signal intensity on T2-weighted imaging and enhancing pattern
Lesion type Tumor number Size (cm) Hyper on T2WI/T2*EPI
Precontrast Postcontra
HCC 11 2.3 1.3 7 8
Benign nodule 6 1.6 0.4 0 0
a The nodules was enlarged in follow-up computed tomography and magnetic re
AP ¼ accumulation phase; EP ¼ equilibrium phase; FS-T1WI ¼ T1-weighted
hyperintense; T2*EPI ¼ T2*-echo planar imaging; T2WI ¼ T2-weighted imaging.
Values are depicted as mean standard deviation.Ferucarbotran-enhanced MRI with conventional criteria
( p¼ 0.002).
Only 1 of 11 HCC nodules in the Ferucarbotran-enhanced
group and 3 of 15 HCC nodules in the gadolinium-enhanced
group showed the washout phenomenon in the equilibrium-
phase T1WI. None of the benign nodules in either group
showed washout phenomenon in the equilibrium-phase T1WI.
4. Discussion
Hyperintense nodules on unenhanced T1WI against
a background of cirrhosis are a diagnostic challenge in daily
practice. In our results, the sensitivity was significantly higher
in Ferucarbotran-enhanced MRI with accumulation-phase
FS-T1WI than gadolinium-enhanced ( p¼ 0.01) and Fer-
ucarbotran-enhanced MRI ( p¼ 0.002) in characterization of
the hyperintense nodules on unenhanced T1WI. The statistical
difference was because of the low sensitivity for HCC with the
conventional criteria of gadolinium-enhanced and Ferucarbo-
tran-enhanced MRI. Using the conventional criteria in dis-
tinguishing HCC from benign nodules, the sensitivity was only
53% in the gadolinium-enhanced group and 73% in the
conventional criteria of Ferucarbotran-enhanced group. There
are two possible reasons to explain this. First, 77% of the
HCCs (20/26) in both groups were well-differentiated HCCs
and only 23% (6/26) were moderately HCC in our study
( p< 0.001). This might be because of well-differentiated
HCC frequently presenting hyperintense on the unenhanced
T1WI.14 Li et al. also reported the MR appearance of well-
differentiated HCCs was diverse; only 36% showed hyperin-
tense on T2WI, and 51% showed arterial enhancement during
dynamic study.14 Second, hyperintensity on precontrast T1WI
might mask subtle arterial enhancement and decreased diag-
nostic performance of the dynamic MR study. These two
reasons might explain the low sensitivity for HCC with the
conventional criteria of gadolinium-enhanced MRI in char-
acterization of the T1W hyperintense nodules.
Yu et al. reported dynamic subtraction MR imaging could
be useful for the characterization of T1W hyperintense
lesions.9 However, poor subtraction imaging quality because
of misregistration artifact was encountered in our study. New
MR software with the function of auto-registration might be
needed. Using Ferucarbotran-enhanced accumulation-phase
FS-T1WI in characterization of the T1W hyperintense










imaging with fat suppression; HCC ¼ hepatocellular carcinoma; Hyper ¼
Table 3
Number, size, and signal intensity on T2-weighted imaging and enhancing pattern for T1-weighted hyperintense nodules in gadolinium-enhanced group




Hyper Hypo or iso
HCC 15 2.1 0.8 5 10 8 3
Benign nodule 7 1.8 0.4 0 7 0 0
a Values are depicted as mean standard deviation.
HCC¼ hepatocellular carcinoma; Hyper¼ hyperintense; Hypo¼ hypointense; Iso¼ isointense; T1WI¼ T1-weighted imaging; T2WI¼ T2-weighted imaging.
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The scan time for the accumulation-phase FS-T1WI with
breath-holding is short (18e21 seconds for one breath-
holding, 28e31 seconds for two breath-holdings) and can be
performed immediately after the postcontrast T2WI.
Several studies have shown that the characteristic HCC
profile includes intense arterial uptake but is followed by
contrast washout in the late phase of dynamic imaging tech-
niques including contrast-enhanced US, CT, and MRI.15e17
For the washout phenomenon, only one HCC nodule (1/11)
in the Ferucarbotran-enhanced group and three HCC nodules
(3/15) in the gadolinium-enhanced group depicted washout
phenomenon in equilibrium-phase T1WI in our study. Mean-
while, all of the HCC nodules in the Ferucarbotran-enhanced
group showed hyperintense on accumulation-phase FS-T1WI.
According to our results, the washout phenomenon for HCC
diagnosis seemed to be inappropriate in characterization of
T1W hyperintense nodules.Fig. 1. A 49-y/o man with well-differentiated hepatocellular carcinoma at S3 of th
(A) T1-weighted opposed-phase image showed a hyperintense nodule on S3 of t
(C) Arterial enhancement of the S3 nodule during dynamic T1WI was noted. (
FS-T1WI ¼ T1-weighted imaging with fat suppression; T2WI ¼ T2-weighted imThere are two possible reasons to explain HCC nodules
instead of benign nodules presenting hyperintensity on the Fer-
ucarbotran-enhanced accumulation-phase FS-T1WI. First, the
Kupffer-cell density of theHCCwas lower and the benign nodule
was higher than that of the adjacent normal liver paren-
chyma.10,13,18 The difference of Kupffer-cell density resulted in
the signal intensity loss being higher in liver parenchyma than
HCC nodules on accumulation-phase FS-T1WI. In contrast to
HCC nodules, signal intensity loss of benign nodules was higher
than or similar to that of liver parenchyma on accumulation-
phase FS-T1WI. Second, HCC nodule was enhanced by the T1
effect of the residual circulating SPIO particles.19 These two
reasons might explain why the HCC nodules depicted hyperin-
tense onFerucarbotran-enhanced accumulation-phase FS-T1WI.
According to our results, the use of the Ferucarbotran-enhanced
MR with accumulation-phase FS-T1WI was superior to the
conventional criteria of gadolinium-enhanced MR imaging in
distinguishing HCC from benign nodule among the T1We liver (arrow) underwent Ferucarbotran-enhanced magnetic resonance study.
he liver. (B) The nodule was slightly hyperintense on fat suppression T2WI.
D) The nodule depicted hyperintense on the accumulation-phase FS-T1WI.
aging.
Fig. 2. A 54-y/o man with dysplastic nodules (arrow) at S3 of the liver underwent Ferucarbotran-enhanced MR study. (A) T1W opposed-phase image revealed
a hyperintense nodule on S3 of the liver. (B) The nodule was isointense on fat suppression T2WI. (C) No arterial enhancement of the tumor during dynamic T1W
imaging was noted. (D) The nodule depicted hypointense on the accumulation-phase FS-T1WI.
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with malignant potential also showed hyperintense on the
Ferucarbotran-enhanced accumulation-phase FS-T1WI in the
Ferucarbotran-enhanced group. Sampling error of the liver
biopsy and high-grade differentiation of the benign (dysplastic)
nodule were possible explanations.20e22 However, that benign
nodule might present hyperintense on accumulation-phase
FS-T1WI should be kept in mind.
This study had several limitations. First, the study was
retrospective. Imaging with Ferucarbotran and gadolinium was
not performed in the same patient population. However, the
histological classification and tumor size of T1W hyperintense
nodules in the two populations was similar in our study.Table 4
The results of HCC diagnosis for characterization of the T1-weighted hyperintense
shown








DN¼ dysplastic nodule; FS-T1WI¼ T1-weighted imaging with fat suppressio
¼ nodule was diagnosis as dysplastic nodule.Second, a majority of the tumor diagnoses were based on
needle biopsy. Problems of sampling error and sampling
variation are always inherent in this kind of examination. It is
a known shortcoming in most comparative studies. Third, the
patient population of both imaging groups in our study was
small. Further investigations with larger patient population and
prospective studies are needed.
In conclusion, Ferucarbotran-enhanced MRI with accumu-
lation-phase FS-T1WI is superior to gadolinium-enhancedMRI
in characterization of T1Whyperintense nodulewithin cirrhotic
liver. T1W hyperintense nodule within cirrhotic liver depicting
hyperintense on Ferucarbotran-enhanced accumulation-phase
FS-T1WI should be investigated aggressively.nodules in the Ferucarbotran-enhanced and gadolinium-enhanced groups are
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n; HCC¼ hepatocellular carcinoma; þ¼ nodule was diagnosed as HCC;
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